The following transactions have also occurred at Marigold. 1. 2. 3. 4. 5. 6. Options were granted on July 1, 2024, to purchase 180,000 shares at $16 per share. Although no options were exercised during fiscal year 2025, the average price per common share during fiscal year 2025 was $20 per share. Each bond was issued at face value. The 9% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2024. The preferred stock was issued in 2024. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2025. The 980,000 shares of common stock were outstanding for the entire 2025 fiscal year. Net income for fiscal year 2025 was $1,520,000, and the average income tax rate is 20%. For the fiscal year ended June 30, 2025, calculate the following for Marigold Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. 2.45.) a. Basic earnings per share. Basic earnings per share b. Diluted earnings per share. $ LA Diluted earnings per share $

Intermediate Accounting: Reporting And Analysis
3rd Edition
ISBN:9781337788281
Author:James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:James M. Wahlen, Jefferson P. Jones, Donald Pagach
Chapter16: Retained Earnings And Earnings Per Share
Section: Chapter Questions
Problem 24P: Frost Company has accumulated the following information relevant to its 2019 earningsper share. 1....
icon
Related questions
Question
The following transactions have also occurred at Marigold.
1.
2.
3.
4.
5.
6.
Options were granted on July 1, 2024, to purchase 180,000 shares at $16 per share. Although no options were exercised
during fiscal year 2025, the average price per common share during fiscal year 2025 was $20 per share.
Each bond was issued at face value. The 9% convertible bonds will convert into common stock at 50 shares per $1,000 bond.
The bonds are exercisable after 5 years and were issued in fiscal year 2024.
The preferred stock was issued in 2024.
There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2025.
The 980,000 shares of common stock were outstanding for the entire 2025 fiscal year.
Net income for fiscal year 2025 was $1,520,000, and the average income tax rate is 20%.
For the fiscal year ended June 30, 2025, calculate the following for Marigold Pharmaceutical Industries. (Round answers to 2 decimal
places, e.g. 2.45.)
a. Basic earnings per share.
Basic earnings per share $
b. Diluted earnings per share.
Diluted earnings per share $
Transcribed Image Text:The following transactions have also occurred at Marigold. 1. 2. 3. 4. 5. 6. Options were granted on July 1, 2024, to purchase 180,000 shares at $16 per share. Although no options were exercised during fiscal year 2025, the average price per common share during fiscal year 2025 was $20 per share. Each bond was issued at face value. The 9% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2024. The preferred stock was issued in 2024. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2025. The 980,000 shares of common stock were outstanding for the entire 2025 fiscal year. Net income for fiscal year 2025 was $1,520,000, and the average income tax rate is 20%. For the fiscal year ended June 30, 2025, calculate the following for Marigold Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. 2.45.) a. Basic earnings per share. Basic earnings per share $ b. Diluted earnings per share. Diluted earnings per share $
Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and
diluted earnings per share and the related disclosure for Marigold's financial statements. Below is selected financial information for
the fiscal year ended June 30, 2025.
Long-term debt
Notes payable, 10%
9% convertible bonds payable
10% bonds payable
Total long-term debt
Marigold Pharmaceutical Industries
Selected Balance Sheet Information
June 30, 2025
Shareholders' equity
Preferred stock, 6% cumulative, $50 par value, 98,000 shares authorized, 24,500 shares issued and outstanding
Common stock, $1 par, 9,800,000 shares authorized, 980,000 shares issued and outstanding
Additional paid-in capital
Retained earnings
Total shareholders' equity
$1,010,000
5,030,000
5,990,000
$12,030,000
$1,225,000
980,000
4,010,000
6,040,000
$12,255,000
Transcribed Image Text:Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Marigold's financial statements. Below is selected financial information for the fiscal year ended June 30, 2025. Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable Total long-term debt Marigold Pharmaceutical Industries Selected Balance Sheet Information June 30, 2025 Shareholders' equity Preferred stock, 6% cumulative, $50 par value, 98,000 shares authorized, 24,500 shares issued and outstanding Common stock, $1 par, 9,800,000 shares authorized, 980,000 shares issued and outstanding Additional paid-in capital Retained earnings Total shareholders' equity $1,010,000 5,030,000 5,990,000 $12,030,000 $1,225,000 980,000 4,010,000 6,040,000 $12,255,000
Expert Solution
trending now

Trending now

This is a popular solution!

steps

Step by step

Solved in 4 steps with 5 images

Blurred answer
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Intermediate Accounting: Reporting And Analysis
Intermediate Accounting: Reporting And Analysis
Accounting
ISBN:
9781337788281
Author:
James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:
Cengage Learning
Cornerstones of Financial Accounting
Cornerstones of Financial Accounting
Accounting
ISBN:
9781337690881
Author:
Jay Rich, Jeff Jones
Publisher:
Cengage Learning
Managerial Accounting: The Cornerstone of Busines…
Managerial Accounting: The Cornerstone of Busines…
Accounting
ISBN:
9781337115773
Author:
Maryanne M. Mowen, Don R. Hansen, Dan L. Heitger
Publisher:
Cengage Learning